Search clinical trials for: Insulin Lispro Protamine Suspension

Total 423 results

Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) (IOPE)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Brazil, Canada
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) (IOOY)

Diabetes Mellitus Type 2

Korea, Republic of, Hungary, United States, Mexico, Argentina, India, Poland, Taiwan, Spain
Eli Lilly and Company

Completed

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Diabetes Mellitus, Type 2

Turkey, Argentina, Korea, Republic of, Brazil, China, Egypt, India, Spain
Eli Lilly and Company

Completed

A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Romania, Italy, Belgium, Poland, Greece, Germany, United Kingdom, Turkey, Czech Republic, Slovakia
Sanofi

Completed

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

Diabetes Mellitus, Type 2

United States, Puerto Rico
Eli Lilly and Company

Completed

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes (IOOZ)

Diabetes Mellitus, Type 1

Russian Federation, United States, Australia, Greece, Argentina, Hungary, Brazil, Mexico, Romania
Eli Lilly and Company

Completed

Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Sanofi

Completed

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes (PRESCHOOL)

Type 1 Diabetes Mellitus

United States, Austria, Brazil, Chile, Czech Republic, Germany, Hungary, India, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Turkey
Wockhardt

Withdrawn

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects

Bioequivalence in Healthy Subjects

United States
Eli Lilly and Company

Completed

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Taiwan, China, Korea, Republic of
Mannkind Corporation

Completed

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Diabetes Type 2

Brazil, Spain, United States, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, United Kingdom
Eli Lilly and Company

Completed

Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (IONM)

Diabetes Mellitus, Type 2 | Acute Myocardial Infarction

Canada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
Michael Tsoukas
Adocia

Recruiting

Safety and Efficacy of BC LisPram

Type1 Diabetes Mellitus

Canada
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Eli Lilly and Company

Completed

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (IOOV)

Diabetes Mellitus, Type 2

United States, Canada, India, Puerto Rico, Australia, Spain, Netherlands, Hungary, Brazil, Greece, Romania, Argentina
Eli Lilly and Company

Completed

Bioequivalence of Two Lispro Formulations

Healthy Volunteers

Singapore
Adocia

Completed

A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

Germany
Diasome Pharmaceuticals
Integrium

Completed

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) (ISLE-1)

Type 1 Diabetes Mellitus

United States
Adocia
Eli Lilly and Company

Completed

A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants

Healthy Participants

Singapore
Sun Yat-sen University
Eli Lilly and Company; Ministry of Health, China; Amylin Pharmaceuticals, LLC.

Completed

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Newly Diagnosed

China
Inreda Diabetic B.V.

Completed

Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes (FAST 1)

Type 1 Diabetes

Netherlands
Universidad de Guanajuato

Completed

Insulin Schemes for Type 2 Diabetes Control

Type 2 Diabetes Mellitus

Mexico
Adocia
Eli Lilly and Company

Completed

An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

Healthy

Germany
Dance Biopharm Inc.
WCCT Global

Terminated

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Safety and Tolerability

United States
Sanofi

Completed

A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes

Type 1 Diabetes

Germany
Eli Lilly and Company

Completed

Comparison of Insulin Mix25 Versus Mix50 (CLASSIFY)

Type 2 Diabetes Mellitus

Japan, Korea, Republic of, China, Turkey
Diasome Pharmaceuticals
Integrium

Completed

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

Diabetes Mellitus, Type 1

United States
Eli Lilly and Company

Completed

A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes (PRONTO-Pump)

Diabetes Type 1

United States, Spain
Eli Lilly and Company

Completed

Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (S019)

Diabetes Mellitus, Type 2

Croatia, Poland, Romania, South Africa, Turkey
Eli Lilly and Company

Completed

A Study for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Brazil, Canada, Mexico, India, Australia, China, Korea, Republic of
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects

Clamp Study

Russian Federation
Biodel

Completed

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

United States
Diasome Pharmaceuticals

Completed

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Diabetes Mellitus, Type 1

United States
Eli Lilly and Company

Completed

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy (PRONTO-Pump-2)

Type 1 Diabetes Mellitus

Spain, United States, France, Israel, Australia, Germany, Italy, Puerto Rico, Austria, Hungary, Canada
Fudan University
Novo Nordisk A/S

Unknown

Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin

Type 2 Diabetes Mellitus

China
University of Cambridge

Completed

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4)

Type 1 Diabetes

United Kingdom
Eli Lilly and Company

Completed

A Study of a New LY900014 Formulation in Healthy Participants

Healthy

Singapore
Chongqing Medical University

Completed

Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro Using Needle-Free Jet Injection Technology

Healthy

China
Eli Lilly and Company

Completed

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Diabetes Mellitus, Type 1

France, Germany, Hungary
Hompesch, Marcus, M.D.
Profil Institute for Clinical Research, Inc.

Unknown

PK/PD Study of Intranasal Insulin in Type I Diabetes

Type 1 Diabetes

United States
Biodel

Completed

Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes

Type 1 Diabetes
Third Affiliated Hospital, Sun Yat-Sen University
Guangdong Provincial Department of Science and Technology

Unknown

Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes (COGFOST)

Diabetes Mellitus, Type 2

China
Graydon Meneilly

Suspended

Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique

Diabetes Mellitus | Lipohypertrophy

Canada
Medical University of Graz
European Commission

Completed

Absorption of Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations

Type 1 Diabetes

Austria
Diasome Pharmaceuticals
Integrium

Completed

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

Type1 Diabetes Mellitus

United States
Profil Institut für Stoffwechselforschung GmbH

Completed

A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1

Diabetes Mellitus

Germany
Sun Yat-sen University

Completed

Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes

Diabetes Mellitus, Type 2

China
Sanofi

Completed

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus (PUMP)

Diabetes Mellitus, Type 1

France, Australia, Spain, Sweden, United States, Austria, Hungary, Israel, Italy, United Kingdom, Korea, Republic of, Netherlands
Novo Nordisk A/S

Completed

Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China

3

Subscribe